Company
Australia's first biotech accelerator program focused on synthetic biology
Every investor coverage indicates participated in a round SynBio 10x raised.
Companies SynBio 10x acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
Stories naming SynBio 10x. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
CSIRO and Main Sequence's updated synthetic biology report projects a $30 billion annual sector and 50,000 jobs by 2040, citing startup capital raised, research grants, and the 2022 launch of UNSW Founders' SynBio 10x accelerator.
Australia's Main Sequence fund promotes Gabrielle Munzer to Partner to lead its biotech push; the article also covers her finance background, the firm's company-building model, a UNSW accelerator, and recent diverse hires.